Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at UBS Group

UBS Group started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report published on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $38.00 price target on the stock.

Other research analysts also recently issued research reports about the company. Royal Bank of Canada cut their price target on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. JMP Securities reiterated a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. Finally, HC Wainwright cut their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, January 10th. Eleven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics has a consensus rating of “Buy” and a consensus target price of $64.44.

Jasper Therapeutics Trading Up 12.9 %

Shares of NASDAQ JSPR opened at $6.20 on Thursday. The stock has a fifty day simple moving average of $13.12 and a two-hundred day simple moving average of $17.63. Jasper Therapeutics has a 1-year low of $4.55 and a 1-year high of $31.01. The firm has a market cap of $93.01 million, a price-to-earnings ratio of -1.31 and a beta of 2.11.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of JSPR. Jane Street Group LLC purchased a new position in Jasper Therapeutics in the 3rd quarter worth approximately $251,000. Samsara BioCapital LLC raised its holdings in Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after buying an additional 59,642 shares during the last quarter. Barclays PLC raised its stake in shares of Jasper Therapeutics by 320.7% during the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after acquiring an additional 12,308 shares during the last quarter. Wellington Management Group LLP bought a new position in Jasper Therapeutics during the 3rd quarter valued at approximately $447,000. Finally, Ally Bridge Group NY LLC lifted its stake in Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after acquiring an additional 180,852 shares during the period. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.